<DOC>
	<DOC>NCT00635076</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.</brief_summary>
	<brief_title>A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder</brief_title>
	<detailed_description>Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>A primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of panic disorder with or without agoraphobia based on the MiniInternational Neuropsychiatric Interview for Children and Adolescents Subjects with an average of 1) at least one 4symptom panic attack per week over the last 4 weeks before screening; 2) at least one 4symptom panic attack per week over the last 4 weeks before baseline; and 3) at least one 4symptom panic attack in the 7 days prior to baseline To enter Study A6131007, subjects must have completed Study A6131002, had an acceptable tolerability to study drug, and in the clinical judgment of the investigator, could have benefited from continued study treatment. Subjects must continue to meet all of the exclusion criteria enumerated in the Acute Efficacy Study (Protocol A6131002) with the following exception: Subjects will be allowed to undergo cognitivebehavioral or other panicspecific therapy and any other psychotherapy (e.g., supportive and/or family therapy) during the expected study period in this study.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>